BioCentury

7:00 AM GMT, Apr 28, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Progenics chronicles

Progenics chronicles

Progenics' stock has had a bumpy ride from the newsflow related to the methylnaltrexone compound it in-licensed from UR Labs in 2001. The company ended last week up 95% - gaining $6.52 to $13.40 - on FDA

Read the full 381 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.